- Women ≥ 18 years old with a diagnosis of primary, recurrent or progressive uterine, ovarian, fallopian tube or peritoneal carcinosarcoma, for whom treatment with combination paclitaxel and carboplatin is recommended. Eastern Cooperative Oncology Group (ECOG) performance status 0-2. Tissue available for translational study (paraffin block or new biopsy). 5. Adequate bone marrow, renal, and hepatic function per study requirements. Women of childbearing potential must be willing to use a highly effective form of birth control during the study and for 6 months after the last dose of galunsertib.